New regulations set stage for updated ESG considerations.
Adam Lohr
Advertisement
Life sciences senior analyst, RSM US LLP
Articles by Adam Lohr
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
How are the Drug Pricing Negotiations Impacting Pharma's Relationship with DC?
2
Excellergy Announces Launch with $70 Million Series A Funding Aiming to Advance Pipeline of Trifunctional Effector Cell Response Inhibitors
3
Policy Whiplash in Pharma: Navigating Volatility with Strategic Clarity
4
